Diyong Xu Acquires 1,875,000 Shares of Q32 Bio (NASDAQ:QTTB) Stock

Q32 Bio Inc. (NASDAQ:QTTB) Director Diyong Xu bought 1,875,000 shares of the stock in a transaction on Thursday, May 28th. The stock was acquired at an average cost of $8.00 per share, for a total transaction of $15,000,000.00. Following the acquisition, the director directly owned 3,502,987 shares in the company, valued at approximately $28,023,896. The trade was a 115.17% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Q32 Bio Stock Performance

Shares of NASDAQ QTTB opened at $12.64 on Wednesday. Q32 Bio Inc. has a 12 month low of $1.35 and a 12 month high of $13.19. The company has a market cap of $214.37 million, a P/E ratio of 4.75 and a beta of 0.27. The business’s 50 day moving average is $6.45 and its two-hundred day moving average is $4.72. The company has a quick ratio of 5.36, a current ratio of 5.36 and a debt-to-equity ratio of 0.04.

Q32 Bio (NASDAQ:QTTB) last announced its quarterly earnings data on Tuesday, May 5th. The company reported ($0.54) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.68) by $0.14. On average, equities analysts expect that Q32 Bio Inc. will post -1.96 EPS for the current year.

Wall Street Analyst Weigh In

Several research firms have recently issued reports on QTTB. Weiss Ratings upgraded shares of Q32 Bio from a “sell (d+)” rating to a “hold (c-)” rating in a report on Monday, May 11th. Mizuho assumed coverage on Q32 Bio in a research note on Friday, May 22nd. They set an “outperform” rating and a $14.00 price target on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $13.00 price target on shares of Q32 Bio in a report on Tuesday, May 5th. Zacks Research downgraded Q32 Bio from a “strong-buy” rating to a “hold” rating in a research report on Monday, May 18th. Finally, Cantor Fitzgerald began coverage on Q32 Bio in a report on Monday, May 18th. They set an “overweight” rating on the stock. Three analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $13.50.

Hedge Funds Weigh In On Q32 Bio

Several institutional investors have recently bought and sold shares of the business. Marshall Wace LLP acquired a new position in shares of Q32 Bio during the second quarter worth approximately $25,000. ADAR1 Capital Management LLC acquired a new stake in Q32 Bio in the fourth quarter worth $66,000. XTX Topco Ltd acquired a new stake in Q32 Bio during the 4th quarter worth $68,000. Cetera Investment Advisers bought a new position in shares of Q32 Bio during the 1st quarter valued at about $133,000. Finally, HRT Financial LP lifted its stake in Q32 Bio by 66.5% in the fourth quarter. HRT Financial LP now owns 24,698 shares of the company’s stock valued at $81,000 after buying an additional 9,862 shares in the last quarter. Institutional investors own 31.32% of the company’s stock.

About Q32 Bio

Q32 Bio Inc, a clinical-stage biotechnology company, develops biologic therapeutics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction in the United States. Its lead product candidate is ADX-097, a humanized anti-C3d monoclonal antibody fusion protein to restore complement regulation, which has completed Phase I clinical trial for the treatment of renal and other complement-mediated diseases of high unmet need, including lupus nephritis, immunoglobulin A nephropathy, complement component 3 glomerulopathy, and anti-neutrophil cytoplasmic antibody-associated vasculitis.